VIKING THERAPEUTICS INC. overview

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PR Newswire SAN DIEGO, March 26, 2025 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO , March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations PR Newswire BASEL, Switzerland, March 11, 2025 CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides...

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 PR Newswire SAN DIEGO, March 11, 2025 Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make Prepayments Totaling...

Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, March 4, 2025 SAN DIEGO , March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: Leerink Partners Global...

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update PR Newswire SAN DIEGO, Feb. 5, 2025 Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway Strong Year-End Cash Position of $903 Million SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a...

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025 PR Newswire SAN DIEGO, Jan. 29, 2025 Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PR Newswire NEW YORK, Jan. 14, 2025 NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Viking and certain of its...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PR Newswire NEW YORK, Jan. 8, 2025 NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Viking and certain of its...